May 22, 2015
Patients with chronic graft-vs.-host disease who were treated with thymosin β4 eye drops (RGN-259, 0.1%) experienced statistically significant improvements in signs and symptoms, according to a study published in Cornea.
Sosne and colleagues conducted a randomized, double-masked, placebo-controlled phase 2 clinical trial at two U.S. sites. Researchers treated nine men and women older than 18 years with severe dry eye with either Tβ4, a naturally occurring 43 amino acid peptide found in high concentrations in most tissues and cells, or placebo six times a day. The 56-day trial included a 28-day follow-up.